세계의 강심제 시장 보고서(2025년)
Cardiotonic Agents Global Market Report 2025
상품코드 : 1760498
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,444,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,314,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,184,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

강심제 시장 규모는 향후 몇 년 동안 빠르게 성장할 것으로 예상되며, 2029년까지 12.6%의 CAGR로 50억 6,000만 달러 규모로 성장할 것으로 예상됩니다. 예측 기간 동안의 성장은 심혈관계 사망률 증가, 강심제 강화에 초점을 맞춘 임상시험 증가, 심혈관계 약물 개발에 대한 민관 협력 확대, 심장 합병증으로 인한 입원 증가, 맞춤형 심혈관계 의료에 대한 수요 증가에 기인하는 것으로 보입니다. 예측 기간 동안 주요 동향으로는 펩타이드 기반 개발, 이중 기전 약물 개발, 약리유전체학 통합, 주사제형 디포제제 혁신, 병용요법의 발전 등이 있습니다.

심혈관질환의 유병률 증가는 향후 몇 년 동안 강심제 시장의 성장을 촉진할 것으로 예상됩니다. 심혈관질환(CVD)은 관상동맥질환, 심부전, 부정맥, 뇌졸중 등 심장과 혈관에 영향을 미치는 질환을 포함합니다. 이러한 증가는 포화지방산, 트랜스지방산, 염분, 당분을 많이 함유한 건강에 해로운 식습관이 주요 원인이며, 비만, 고혈압, 콜레스테롤 수치 상승의 한 원인이 되고 있습니다. 강심제는 심근의 효율과 수축력을 높여 혈액순환을 개선하고 다양한 심혈관계 질환의 증상을 완화합니다. 예를 들어, 2023년 12월 호주 정부 기관인 호주 보건 복지 연구소는 관상동맥성 심장 질환(CHD)으로 인한 의사 진단 사망자 수가 2021년 1만 4,100명에서 2022년 1만 4,900명으로 증가했다고 보고했습니다. 결과적으로 심혈관질환의 유병률 증가는 강심제 시장 성장에 기여하고 있습니다.

강심제 시장의 주요 기업들은 급성 심부전 및 심인성 쇼크의 심장 기능 개선을 목적으로 하는 단기 강심제와 같은 혁신적인 제품을 개발하고 있습니다. 단기 강심제는 심장의 수축력을 일시적으로 증가시키고 심박출량을 증가시키는 데 사용됩니다. 예를 들어, 2023년 6월 영국 제약회사 Hikma Pharmaceuticals plc는 250mg/20mL 바이알 용량의 도부타민 주사제 USP를 출시했습니다. 이 주사액은 심장 질환이나 심장 수술 후 흔히 발생하는 심장 수축력 저하로 인한 심근 탈락을 앓고 있는 성인에게 단기간의 강심 작용을 제공합니다. 도부타민은 베타1 수용체를 자극하여 심근 수축력과 심박출량을 1-2분 내에 빠르게 증가시킵니다. 이 주사는 정맥으로 투여되며, 보통 병원에서 엄격한 의학적 관리 하에 사용됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Cardiotonic agents are a group of drugs that enhance the strength and efficiency of heart muscle contractions, thereby improving the heart's ability to pump blood. These medications are primarily used to manage heart failure and certain arrhythmias by boosting cardiac output and enhancing blood circulation.

The main categories of cardiotonic agents include digitalis glycosides, phosphodiesterase inhibitors, cardioprotectants, sympathomimetic agents, and others. Digitalis glycosides are compounds extracted from the Digitalis plant, used to treat heart conditions by increasing contraction force and regulating heart rhythm. These drugs can be administered orally, intravenously, or via other methods, with common dosage forms including tablets and solutions. They are utilized in a variety of clinical scenarios such as cardiac surgeries, atrial fibrillation, heart failure, pulmonary hypertension, among others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The cardiotonic agents market research report is one of a series of new reports from The Business Research Company that provides cardiotonic agents market statistics, including cardiotonic agents industry global market size, regional shares, competitors with a cardiotonic agents market share, cardiotonic agents market segments, market trends and opportunities, and any further data you may need to thrive in the cardiotonic agents industry. This cardiotonic agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiotonic agents market size has grown rapidly in recent years. It will grow from $2.78 billion in 2024 to $3.14 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth during the historic period can be attributed to the rising prevalence of heart failure, an expanding elderly population, an increasing incidence of coronary artery disease, greater adoption of sedentary lifestyles, and the growing burden of hypertension and diabetes.

The cardiotonic agents market size is expected to see rapid growth in the next few years. It will grow to $5.06 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to increasing cardiovascular mortality rates, a rise in clinical trials focused on enhanced cardiotonic formulations, expanding public-private collaborations in cardiovascular drug development, growing hospital admissions related to cardiac complications, and heightened demand for personalized cardiovascular medicine. Key trends during the forecast period include the development of peptide-based cardiotonic agents, creation of dual-mechanism drugs, integration of pharmacogenomics, innovation in injectable depot formulations, and advancement of combination therapies.

The increasing prevalence of cardiovascular diseases is expected to drive growth in the cardiotonic agents market in the coming years. Cardiovascular diseases (CVDs) include a group of disorders affecting the heart and blood vessels, such as coronary artery disease, heart failure, arrhythmias, and stroke. This rise is largely attributed to unhealthy diets rich in saturated fats, trans fats, salt, and added sugars, which contribute to obesity, high blood pressure, and elevated cholesterol levels. Cardiotonic agents work by enhancing the heart muscle's efficiency and contraction strength, thereby supporting improved blood circulation and alleviating symptoms in various cardiovascular conditions. For example, in December 2023, the Australian Institute of Health and Welfare, an Australian government agency, reported that doctor-certified deaths due to coronary heart disease (CHD) increased from 14,100 in 2021 to 14,900 in 2022. Consequently, the rising prevalence of cardiovascular diseases is fueling the growth of the cardiotonic agents market.

Leading companies in the cardiotonic agents market are developing innovative products, including short-term inotropic drugs, aimed at improving cardiac performance in acute heart failure and cardiogenic shock. Short-term inotropic drugs are used to temporarily increase the heart's contractility, which enhances cardiac output. For instance, in June 2023, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, launched Dobutamine Injection, USP, in a 250 mg/20 mL vial. This injection provides short-term inotropic support for adults suffering from cardiac decompensation due to reduced heart contractility, often caused by heart disease or following cardiac surgery. Dobutamine stimulates beta-1 receptors to boost heart muscle contractility and cardiac output with a rapid onset of 1 to 2 minutes. The injection is administered intravenously and is typically used in hospital settings under close medical supervision.

In April 2023, SK Capital Partners LP, a US-based capital market company, acquired Apotex Pharmaceutical Holdings Inc. for an undisclosed sum. This acquisition aims to accelerate Apotex's growth and innovation by leveraging SK Capital's expertise to expand global access to affordable, high-quality pharmaceuticals. Apotex Pharmaceutical Holdings Inc., based in Canada, manufactures a cardiotonic agent marketed under the brand name Apo-Digoxin.

Major players in the cardiotonic agents market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, and Deccan Nutraceuticals Pvt. Ltd.

North America was the largest region in the cardiotonic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cardiotonic agents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cardiotonic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cardiotonic agents market consists of sales of digoxin, milrinone, dobutamine, levosimendan, and amrinone. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cardiotonic Agents Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cardiotonic agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cardiotonic agents ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cardiotonic agents market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Cardiotonic Agents Market Characteristics

3. Cardiotonic Agents Market Trends And Strategies

4. Cardiotonic Agents Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cardiotonic Agents Growth Analysis And Strategic Analysis Framework

6. Cardiotonic Agents Market Segmentation

7. Cardiotonic Agents Market Regional And Country Analysis

8. Asia-Pacific Cardiotonic Agents Market

9. China Cardiotonic Agents Market

10. India Cardiotonic Agents Market

11. Japan Cardiotonic Agents Market

12. Australia Cardiotonic Agents Market

13. Indonesia Cardiotonic Agents Market

14. South Korea Cardiotonic Agents Market

15. Western Europe Cardiotonic Agents Market

16. UK Cardiotonic Agents Market

17. Germany Cardiotonic Agents Market

18. France Cardiotonic Agents Market

19. Italy Cardiotonic Agents Market

20. Spain Cardiotonic Agents Market

21. Eastern Europe Cardiotonic Agents Market

22. Russia Cardiotonic Agents Market

23. North America Cardiotonic Agents Market

24. USA Cardiotonic Agents Market

25. Canada Cardiotonic Agents Market

26. South America Cardiotonic Agents Market

27. Brazil Cardiotonic Agents Market

28. Middle East Cardiotonic Agents Market

29. Africa Cardiotonic Agents Market

30. Cardiotonic Agents Market Competitive Landscape And Company Profiles

31. Cardiotonic Agents Market Other Major And Innovative Companies

32. Global Cardiotonic Agents Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cardiotonic Agents Market

34. Recent Developments In The Cardiotonic Agents Market

35. Cardiotonic Agents Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기